| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Revenue | $5.13B | +167.9% |
| Cost of Revenue | $1.45B | +194.7% |
| R&D Expense | $352.0M | +528.6% |
| SG&A Expense | $651.0M | +447.1% |
| Operating Income | -$46.0M | -114.2% |
| Interest Expense | $1.15B | +228.9% |
| Pre-tax Income | -$1.22B | -63.3% |
| Income Tax | -$48.0M | -140.3% |
| Net Income | -$1.17B |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $3.13B | +129.7% |
| Short-term Investments | $34.0M | — |
| Accounts Receivable | $3.17B | +660.8% |
| Current Assets | $7.49B | +290.8% |
| Total Assets | $49.30B | +176.5% |
| Current Liabilities | $16.44B | +231.3% |
| Long-term Debt | $21.37B | +169.6% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | $3.06B | +11.2% |
| Capital Expenditures | $10.31B | +18.5% |
| Investing Cash Flow | -$10.27B | -18.6% |
| Financing Cash Flow | $9.31B | +24.7% |
| Free Cash Flow | -$7.25B | -21.8% |
| -35.2% |
| EPS (Basic) | -$2.75 | +36.0% |
| EPS (Diluted) | -$2.81 | +34.7% |
| Total Liabilities |
| $45.97B |
| +178.2% |
| Stockholders' Equity | $3.33B | +906.3% |